Trial ID or NCT#

NCT02388295

Status

RECRUITING

Purpose

AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.

Official Title

A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy

Eligibility Criteria

Ages Eligible for Study: 30 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Veronica E. Santini, MD, MA
Movement disorders specialist
Clinical Assistant Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM